Recombinant Human TNF-alpha Protein 210-TA-005 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human TNF-alpha Protein
CompanyR&D Systems, a Bio-Techne Brand
Price $137.00Supplier Page View Company Product Page
Catalog Number210-TA-005
Size5 ug (also 20 ug, 100 ug)
SpeciesHuman
Molecule NameTNF-alpha
Source/Expression SystemE. coli-derived Recombinant Human TNF-alpha Protein
FormatLyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein
Purity>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Molecular WeightObserved: 17 kDa, reducing conditions
Theoretical: 17 kDa
ApplicationsBioactivity
Conjugate/TagUnconjugated
NCBI Full Gene Nametumor necrosis factor
NCBI Gene AliasesTNFSF2, DIF, TNF-alpha, TNLG1F, TNFA
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Development of autologous in vitro vascular models for use in preclinical biotherapeutic developmentBlood Vessels, Thrombosis & HemostasisMay 1, 2026Emma Lund, Alexander Silvester, Daniel Thwaites, Yasmin Bennour, Matthew McKechnie, Ross Beaumont, James Munday, Christopher Cooper217669, EMD Millipore); 100 ng/mL IL-1β (catalog no. 201-LB-005, Bio-Techne) and TNFα (catalog no. 210-TA-005, Bio-Techne) or 10% heat-inactivated human AB serum and 1% penicillin/streptomycin RPMI 1640 medium

(2) Mitochondria-Targeted Hydrogen Sulphide Delivery via an Adhesive Hydrogel Modulates Inflammation and Oxidative Stress in Diabetic WoundsGelsMarch 17, 2026Mandeep Kaur Marwah, Hala Shokr, Yukta Sameer Hindalekar, Mohamad Anas Al Tahan, Karan Rana, Lissette Sanchez-Aranguren, Maymunah Sarr, Jacob Baxandall, Katy Mcgonigal, Bahareh Hassanzadeh, et al.L64G) was obtained from BASF (Ludwigshafen, Germany). Tumour necrosis factor-alpha (TNF-α; catalogue #210-TA-005) was obtained from R&D Systems (Abingdon, UK). Ultrapure water was prepared using a Milli-Q purification

(3) Mechanisms of HIV Latency in Hematopoietic Progenitors: GFI1 as a Key RegulatorbioRxivFebruary 24, 2026Jackline A. Onyango, Chen Li, Cuie Chen, W Miguel Disbennett, Maria C. Virgilio, Mark M. Painter, Valeri H. Terry, Barkha Ramnani, Joshua D. Welch, Kathleen L. Collinsand either pcDNA-EV or GFI1. For NF-κB activation, cells were treated with TNF-α (R&D Systems, cat# 210-TA-005). To inhibit NF-κB activation, cells were co-treated with an IKK inhibitor (IKK2 inhibitor VI, Cayman Chemical

(4) Naringenin Loaded Hydrogel Supports Wound Repair in a Cell Model of Diabetic SkinPharmaceutical ResearchJanuary 31, 2026Mandeep Kaur Marwah, Yukta Sameer Hindalekar, Karan Rana, Hala Shokr, Mohamad Anas Al Tahan, Lissette Sanchez-Aranguren, Maymunah Sarr, Rosie Kainth, Parmida Babaei, Humaa Asif, et al.purification system (Millipore, Billerica, MA, US). Tumour necrosis factor-alpha (TNF-α) (Cat. No. 210-TA-005) was purchased from R&D Systems, Abingdon, UK. Gel Formulation The adhesive hydrogel formulation was

(5) Lactobacillus murinus Induces CYP1A1 Expression and Modulates TNF-Alpha-Induced Responses in a Human Intestinal Epithelial Cell ModelInt J Mol SciDecember 2, 2025Husnain Ahmed, Azam A. Sher, Julia A. Bell, Linda S. Mansfieldsourced from Sigma-Aldrich. Recombinant human tumor necrosis factor-alpha (TNF-α) protein (Catalog No. 210-TA-005) was purchased from R&D Systems (Minneapolis, MN, USA). 4.2. Bacterial Culture The Lactobacillus murinus

(6) Formulation and In Vitro Characterisation of Withaferin A-Loaded Liposomal Gels for the Topical Management of Chronic Inflammatory Skin ConditionsBr J Biomed SciDecember 1, 2025Mandeep Kaur Marwah, Hala Shokr, Karan Singh Rana, Yukta Sameer Hindalekar, Rosie Kainth, Parmida Babaei, Shakil Ahmad100 nm, and 50 nm, were obtained from Sigma-Aldrich. Tumour necrosis factor-alpha (TNF-α) (Cat. No. 210-TA-005) was purchased from R&D Systems, Abingdon, UK. Cell Culture and Treatment Primary Human Umbilical

(7) IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancerMol CancerOctober 28, 2025Ritsu Ibusuki, Eiji Iwama, Atsushi Shimauchi, Hiromu Kawano, Shun Mizusaki, Satoshi Nakamura, Yui Miyazaki, Yu Inutsuka, Mikiko Hashisako, Taishi Harada, et al.tocilizumab (Chugai Pharmaceutical, Tokyo, Japan) were stored at − 20 °C. Recombinant human TNF-α (#210-TA-005, R&D Systems), recombinant human IFN-γ (#300-02, Peprotech), and recombinant human IL-6 (#206-IL, R&D

(8) Modeling functional responses to pollutant exposure using modular hydrogel supported vascularized alveolosphere-on-a-chipBiomaterials ScienceOctober 21, 2025Sajeesh Kumar Madhurakkat Perikamana, Vardhman Kumar, Pankaj Mogha, Lavonia Duncan, Nikki Angel, Aleksandra Tata, Sairam V. Jabba, Sven Eric Jordt, Purushothama Rao Tata, Shyni Varghesevascularized alveoli-on-a-chip using l(−)-menthol (125401000, Thermo Fisher Scientific) or TNF-α (R&D systems, 210-TA-005), which was used as the positive control. 1 mM of menthol or 100 ng ml−1 TNF-α was introduced into the

(9) Positionally distinct interferon-stimulated dermal immune-acting fibroblasts promote neutrophil recruitment in Sweet's syndromeJournal of Allergy and Clinical ImmunologyOctober 1, 2025Kellen J. Cavagnero, Julie Albright, Fengwu Li, Edward Liu, Tatsuya Dokoshi, Rachael Bogle, Joseph Kirma, J. Michelle Kahlenberg, Allison C. Billi, Jennifer Fox, et al.Systems [Minneapolis, Minn]; catalog no. 11100-1; dose 5 ng/mL), rhTNF-α (R&D Systems; catalog no. 210-TA-005; dose 10 ng/mL), or rhIFN-γ (R&D Systems; catalog no. 285-IF-100; dose 5 ng/mL). After 6 hours of stimulation,

(10) RNA Polymerase III Regulates HIV Replication and LatencyVirusesSeptember 20, 2025Thompson L, Jamal I, Das J, Dang C, Hong Z, Katz D, Bosque A, Singh VB.

(11) Platelet factor 4 modulates endothelial cell antimicrobial activity to enhance bacterial clearance and improve sepsis outcomesbioRxiv : the preprint server for biologySeptember 3, 2025Ngo ATP, Ortmann W, Skidmore A, Kim H, Oberg J, Sarkar A, Bochenek V, Levine N, Rauova L, Chernysh I, et al.

(12) Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulatorProceedings of the National Academy of Sciences of the United States of AmericaApril 1, 2025Molitor TP, Hayashi G, Lin MY, Dunn CJ, Peterson NG, Poston RG, Kurnellas MP, Traver DA, Patel S, Akgungor Z, et al.

(13) Therapeutic potential of AAV2-shmTOR gene therapy in reducing retinal inflammation and preserving endothelial Integrity in age-related macular degenerationScientific reportsMarch 19, 2025Kim J, Moon SY, Kang HG, Kim HJ, Choi JS, Lee SHS, Park K, Won SY.

(14) Multi-omic integration with human DRG proteomics highlights TNFα signalling as a relevant sexually dimorphic pathwaybioRxiv : the preprint server for biologyMarch 17, 2025Barry AM, Sondermann JR, Lesnak JB, Xian F, Franco-Enzástiga Ú, O'Brien JA, Gomez-Varela D, Schackmuth MK, Shiers S, Price TJ, et al.

(15) Migration arrest and transendothelial trafficking of human pathogenic-like Th17 cells are mediated by differentially positioned chemokinesNature communicationsFebruary 26, 2025Parween F, Singh SP, Kathuria N, Zhang HH, Ashida S, Otaizo-Carrasquero FA, Shamsaddini A, Gardina PJ, Ganesan S, Kabat J, et al.

(16) A Nerve-Fibroblast Axis in Mammalian Lung FibrosisbioRxiv : the preprint server for biologyFebruary 11, 2025Ishikawa G, Peng X, Ghincea A, McGovern J, Zielonka J, Jeevanandam A, Shao S, Woo S, Okuno D, Yu S, et al.

(17) The HRAS-binding C2 domain of PLCη2 suppresses tumor-like synoviocytes and experimental arthritis in rheumatoid arthritisExperimental & molecular medicineFebruary 1, 2025Jeon HM, Noh HS, Jeon MG, Park JH, Lee YS, Seo G, Cheon YH, Kim M, Han MK, Park JY, et al.

(18) Extracellular vesicle surface engineering with integrins (ITGAL & ITGB2) to specifically target ICAM-1-expressing endothelial cellsJ NanobiotechnologyJanuary 30, 2025Markus Bergqvist, Kyong-Su Park, Nasibeh Karimi, Lijuan Yu, Cecilia Lässer, Jan Lötvallto the wells. The HMEC-1 cells were treated with 15 ng/mL human tumor necrosis factor alpha (TNF-α; 210-TA-005, R&D systems) overnight to increase ICAM-1 expression on the cells. The washing and blocking of the

(19) The di-leucine motif in the host defense peptide LL-37 is essential for initiation of autophagy in human macrophagesCell reportsJanuary 28, 2025Rekha RS, Padhi A, Frengen N, Hauenstein J, Végvári Á, Agerberth B, Månsson R, Guðmundsson GH, Bergman P.

(20) Periodontal inflammation potentially inhibits hepatic cytochrome P450 expression and disrupts the omega-3 epoxidation pathway in a murine modelJournal of dental sciencesJanuary 1, 2025Daidouji Y, Suzuki S, Wang X, Fahreza RR, Nemoto E, Yamada S.FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). Recombinant tumor necrosis factor (TNF)-α (210-TA-005) was obtained from R&D Systems (Minneapolis, MN, USA). Experimental animals All experimental procedures

Write a Review

(1)

3/17/2023TNF-a from R&D Systems Works Well Liyong Z.To explore the possible signaling pathways involved in BT20, 30 ng/ml TNF-a was used to treat BT20 cells. The results showed that NFKB pathway was activated by TNF-a as evidenced by the expression ... Read Review

Recombinant Human TNF-alpha Protein

TNF-alpha Protein

TNF-alpha Protein

TNF-alpha Protein

TNF-alpha Protein

Recombinant Human TNF-alpha Protein from R&D Systems, a Bio-Techne Brand

Description

R&D Systems, a Bio-Techne Brand

Citations (883)

Reviews

Recombinant Human TNF-alpha Protein from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map